Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1 Billion in U.S. Market Entry

Italy's Angelini Pharma announced on Thursday that it has entered into a definitive agreement to acquire Catalyst Pharmaceuticals in an all-cash transaction valued at approximately $4.1 billion, equivalent to 3.5 billion Euros. Under the terms of the deal, shareholders will receive $31.50 per share, representing a substantial 28% premium over the 30-day volume-weighted average price. This strategic acquisition is designed to establish the Italian firm's direct presence in the U.S. market while strengthening its specialized portfolio in brain health and rare diseases. The transaction is projected to close in the third quarter of 2026, subject to customary closing conditions and regulatory approvals. This move highlights the ongoing consolidation trend within the pharmaceutical sector as global firms seek to diversify their geographic footprint.